Scinai Immunotherapeutics (SCNI) clarifies chairman term and proxy proposal timing
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Scinai Immunotherapeutics Ltd. filed a Form 6-K to clarify language in its proxy materials for the Annual General Meeting of Shareholders scheduled for June 16, 2026. The clarification concerns Proposal No. 6, which addresses extending the Services Agreement with Chairman of the Board Mark Germain.
The original proxy statement mistakenly described the expiry of Mr. Germain’s current director term as the second anniversary of the meeting. The company confirms that his term runs until the second annual meeting of shareholders after the June 16, 2026 meeting, and, if Proposal No. 6 is approved, the extended Services Agreement will expire at that same time.
The report is also incorporated by reference into several existing registration statements on Form S-8 and Form F-3.
Positive
- None.
Negative
- None.
Key Figures
Annual meeting date: June 16, 2026
Commission file number: 001-37353
2 metrics
Annual meeting date
June 16, 2026
Scheduled date of Annual General Meeting of Shareholders
Commission file number
001-37353
Exchange Act registration reference
Key Terms
Form 6-K, Annual General Meeting of Shareholders, Proxy Statement, Services Agreement, +2 more
6 terms
Form 6-K regulatory
"Scinai Immunotherapeutics Ltd. filed a Form 6-K to clarify language"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
Proxy Statement regulatory
"a Form 6-K containing a Notice and Proxy Statement in connection"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
Services Agreement financial
"extension of the term of the Services Agreement with Mr. Mark Germain"
Registration Statements on Form S-8 regulatory
"incorporated by reference into the registrant’s Registration Statements on Form S-8"
Registration Statements on Form F-3 regulatory
"and Form F-3 (File Nos. 333-295698, 333-274078 and 333-276767)"
FAQ
What is Scinai Immunotherapeutics (SCNI) clarifying in this Form 6-K?
Scinai is clarifying how long Chairman Mark Germain’s director term lasts. The proxy mistakenly tied it to the second anniversary of the 2026 meeting; the term actually runs until the second annual meeting of shareholders after that meeting.
When is Scinai Immunotherapeutics’ 2026 Annual General Meeting scheduled?
The Annual General Meeting of Shareholders is scheduled for June 16, 2026. This meeting is the reference point for determining Chairman Mark Germain’s director term and the expiration timing of his Services Agreement if Proposal No. 6 receives shareholder approval.
Does this Form 6-K change any of Scinai’s existing registration statements?
The Form 6-K is incorporated by reference into Scinai’s existing Form S-8 and Form F-3 registration statements. It becomes part of those registration statements from the submission date, unless later filings or documents supersede the information it contains.
Who is affected by the clarified Services Agreement at Scinai Immunotherapeutics?
The clarification directly concerns Chairman of the Board Mark Germain. It confirms that his Services Agreement, if extended under Proposal No. 6, will expire when his director term ends at the second annual shareholders meeting after June 16, 2026.